Dr. Hallahan is the Chairman of the Department of Radiation Oncology at Washington University School of Medicine, Mallinckrodt Institute of Radiology, Elizabeth H. and James S. McDonnell III Distinguished Professor. He has been the primary mentor for more than 24 physician scientists. Most recently, he has mentored 8 Holman Pathway trainees and 3 MSCI clinical investigators. He has also mentored physician scientists within the Vanderbilt Physician Scientists Development Program. He is the past Chairman of the Research Evaluation Committee for ASTRO. He is a past member of the Radiation Therapy and Biology Study Section within the Center for Scientific Review within the National Institutes of Health. Dr. Hallahan has four grants from the National Cancer Institute studying signal transduction to identify molecular targets for drug development and for the development of targeted drug delivery. He will discuss 2 new uses of conformal radiotherapy. First is use of radiation to trigger an immune response in cancer which can be enhanced by immune modulators and antibodies to radiation induced antigens. The second is the use of these radiation guided antibodies to target nanoparticle drug delivery to cancer. The vision for year 2020 is that radiation will be used to conform drug delivery and cancer immune response.
20 years of research in the biological consequences of radiation exposure.
>100 publications in peer reviewed journals
Multiple investigator initiated grants for radiation research from federal funding